The tumor-bearing mice underwent a therapy combining intratumoral CpG-oligodeoxynucleotides (ODN), a ligand of Toll-like receptor 9 (TLR9), and inhibitory interleukin-10 (IL-10) receptor antibodies (anti-IL-10R) (Viaud et al., 2011). Here, IL10 is linked to neoplasm.